Staff turnover in EUR265,041379,666303,148862,672328,367
Staff turnover in EUR265,041379,666303,148862,672328,367
The share: stated in EUR20212022202320242025
Shares outstanding (in mn.)4.734.504.2416.194.24
Dividend per share-0.951.0522.05
Basic earnings per share1.391.05-0.307.76-0.21
P/L in EUR million under IAS/IFRS20212022202320242025
Turnover70.3102.590.1254.197.6
Operating income (EBIT)15.833.86.5158.1-1.8
Earnings before taxes7.424.61.5146.1-0.9
Annual net profit/ loss23.417.3-4.8126.9-3.4
Balance sheet in EUR million under IAS/IFRS20212022202320242025
Assets
Total current assets285.8302.295.0189.8170.5
Total fixed assets548.9447.8420.0417.1399.5
Total assets834.7750.0515.1606.9570.0
Liabilities
Total short-term liabilities22.0192.523.945.323.7
Total long-term liabilities288.7106.592.387.791.1
Total provisions0.50.40.50.60.5
Equity capital524.0451.0398.9474.0455.2
Total liabilities834.7750.0515.1606.9570.0
Management:
Giovanni Di Napoli
Andrea Cherubini
Dominika Spilarova
Egle Gedrimaite
Federico Sommariva
Luigi Longo
Nhan Ngo Dingh
Silvia Miliani
Svetlana Sigalova
Board:
Alessandro Chà
Maria Grazia Roncarolo
John O'Dea
Mauro Ajani
Niall Donnelly
Silvana Perretta
Shareholding in %:
American Century Investment Management, Inc. 0.76
Capital Research & Management Co. (World Investors) 5.55
Cosmo Pharmaceuticals NV 2.99
Gerald Herz 8.00
JPMorgan Asset Management (UK) Ltd. 1.33
Mauro Severino Ajani 35.04
UBS Asset Management Switzerland AG 3.33
Vanguard Capital Management LLC 1.53
Zürcher Kantonalbank (Investment Management) 1.23
dievini Hopp BioTech holding GmbH & Co. KG 3.80
Freefloat 36.43
Address: Riverside II, Sir John Rogerson's Quay, 2 Dublin
T: +353-1-8170370
F: +353-1-8230718
I: http://www.cosmopharma.com
E: